My background in the pharmaceutical industry primarily comes from the generic drug industry. I was involved in the pioneering stage when generic drugs were considered less than equal to a branded pharmaceuticals. Continue Reading
The question moving forward to gain formulary acceptance from PBM’s, is it price reduction or PBM rebates ? Read more from Bloomberg here: Continue Reading
Behind the Push to Keep Higher-Priced EpiPen in Consumers’ Hands- TheWallStreetJournal.com
No comment
This is a strange twist probably driven by lucrative rebates. Read more from The Wall Street Journal: https://www.wsj.com/articles/behind-the-push-to-keep-higher-priced-epipen-in-consumers-hands-1502036741 Continue Reading
Combining generic or otc medications has been a profit strategy by pharmaceutical firms for many years. Paying $1500 per month for a drug that costs less than $20 if purchased separately is greed in my opinion. Continue Reading
PBM’s control access for the branded pharmaceuticals. Removing drugs from their formulary can have a dramatic impact. Biosimilars will impact by reducing the cost by 20-30 percent or more. Interesting to see Continue Reading
Drug middleman Express Scripts is Getting Peppered with Questions About Amazon’s Health Care Interest – CNBC.com
No comment
The management of drug pricing has been a mystery as the PBM is not usually transparent. Amazon can have a dramatic impact on the transparency . Read more from CNBC: Continue Reading
This clip was on NBC Nightly News. It points out the value of pharmacogenetics. We believe that this test can reduce ER visits and hospitalizations. Read more from NBC News here: Continue Reading
When I was a Director of National Accounts for Sandoz/Geneva 15 years ago, they spoke of a new class of drug called Biosimilars . They are just beginning to come to market. Here is one that was just approved Continue Reading
This report clearly shows that the driver of exploding RX costs is the branded single source pharmaceuticals.A number of years back when I was employed by the Sandoz division of Novartis, we were told that they were Continue Reading
Let’s Eliminate The Pharmaceutical ‘Gag Order’ That Costs Patients Money- CTviewpoints.org
No comment
This seems like a good move to give patients ways to save money. https://ctviewpoints.org/2017/05/31/lets-eliminate-the-pharmaceutical-gag-order-that-costs-patients-money/Continue Reading